You are here

Lang Yi Hao tablets

Safety advisory

27 April 2016

Lang Yi Hao tablets pose a serious risk to your health and should not be taken.

The Therapeutic Goods Administration (TGA) has tested product labelled Lang Yi Hao tablets and found that:

Lang Yi Hao packaging and tablets

  • the tablets contain the undeclared substance sildenafil; and
  • the tablets contain the undeclared substance chloramphenicol.

Consumers are advised that sildenafil is a prescription-only substance in Australia, and chloramphenicol is a broad spectrum antibiotic.

The supply of Lang Yi Hao tablets containing undisclosed sildenafil and chloramphenicol is illegal.

Lang Yi Hao tablets have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

TGA investigations have shown that a number of people in Australia may have bought the product online.

Lang Yi Hao tablets

Information for consumers

  • Stop taking Lang Yi Hao tablets and take any remaining tablets to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with the Australian Border Force (ABF) to help stop future shipments of Lang Yi Hao tablets from entering Australia.

If these tablets are found at the border by the ABF they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone: 1800 020 653
Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products